期刊文献+
共找到134篇文章
< 1 2 7 >
每页显示 20 50 100
Transformation of lung adenocarcinoma into small cell lung cancer after treatment with epidermal growth factor receptor tyrosine kinase inhibitors
1
作者 Linwu Kuang Yangkai Li 《Oncology and Translational Medicine》 CAS 2024年第6期286-291,共6页
Epidermal growth factor receptor tyrosine kinase inhibitors effectively improve the prognosis of patients with epidermal growth factor receptor–mutant lung adenocarcinoma.However,acquired resistance inevitably develo... Epidermal growth factor receptor tyrosine kinase inhibitors effectively improve the prognosis of patients with epidermal growth factor receptor–mutant lung adenocarcinoma.However,acquired resistance inevitably develops with small cell lung cancer transformation emerging as a rare but increasingly frequent mechanism of tyrosine kinase inhibitor resistance.This transformation poses significant chal-lenges to the health of patients with lung cancer and complicates their clinical management.This article comprehensively reviews the di-agnostic,predictive,mechanistic,and therapeutic aspects of small cell lung cancer transformation to enhance our understanding and clin-ical awareness of this phenomenon. 展开更多
关键词 small cell lung cancer transformation lung adenocarcinoma EGFR-TKIS sclc Drug resistance
下载PDF
Advances and challenges in immunotherapy of small cell lung cancer 被引量:11
2
作者 Hanfei Guo Lingyu Li Jiuwei Cui 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2020年第1期115-128,共14页
Small cell lung cancer(SCLC) is a highly lethal disease, characterized by early metastasis and rapid growth, and no effective treatment after relapse. Etoposide-platinum(EP) combination has been the backbone therapy o... Small cell lung cancer(SCLC) is a highly lethal disease, characterized by early metastasis and rapid growth, and no effective treatment after relapse. Etoposide-platinum(EP) combination has been the backbone therapy of SCLC over the past 30 years. It is extremely urgent and important to seek new therapies for SCLC. In the past 5 years,immunotherapy, such as immune checkpoint inhibitors programmed cell death protein-1(PD-1), cytotoxic T lymphocyte associatedprotein-4(CTLA-4), has made remarkable achievements in the treatment of patients with SCLC, and it has become the first-line option for the treatment of some patients. Some traditional chemotherapeutic drugs or targeted drugs, such as alkylating agent temozolomide and transcription inhibitor lurbinectedin, have been found to have immunomodulatory effects and are expected to become new immunotherapeutic agents. In this study, we aimed to review the efficacy of new treatments for SCLC and discuss the current challenges and application prospect in the treatment of SCLC patients. 展开更多
关键词 small cell lung cancer(sclc) IMMUNOThERAPY IMMUNE ChECKPOINT INhIBITORS
下载PDF
Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer 被引量:4
3
作者 Soong Goo Jung Jung Han Kim +2 位作者 Hyeong Su Kim Kyoung Ju Kim Ik Yang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2016年第2期161-167,共7页
Background: The criterion of two target lesions per organ in the Response Evaluation Criteria in Solid Tumors (RECIST) version I. 1 is an arbitrary one, being supported by no objective evidence. The optimal number ... Background: The criterion of two target lesions per organ in the Response Evaluation Criteria in Solid Tumors (RECIST) version I. 1 is an arbitrary one, being supported by no objective evidence. The optimal number of target lesions per organ still needs to be investigated. We compared tumor responses using the RECIST 1.1 (measuring two target lesions per organ) and modified RECIST I. 1 (measuring the single largest lesion in each organ) in patients with small cell lung cancer (SCLC). Methods: We reviewed medical records of patients with SCLC who received first-line treatment between January 2004 and December 2014 and compared tumor responses according to the two criteria using computed tomography. Results: There were a total of 34 patients who had at least two target lesions in any organ according to the RECIST 1.1 during the study period. The differences in the percentage changes of the sum of tumor measurements between RECIST 1.1 and modified RECIST 1.1 were all within 13%. Seven patients showed complete response and fourteen showed partial response according to the RECIST I.I. The overall response rate was 61.8%. When assessing with the modified RECIST 1.1 instead of the RECIST 1.1, tumor responses showed perfect concordance between the two criteria (k= 1.0). Conclusions: The modified RECIST 1.I showed perfect agreement with the original RECIST 1.I in the assessment of tumor response of SCLC. Our result suggests that it may be enough to measure the single largest target lesion per organ for evaluating tumor response. 展开更多
关键词 Target lesion Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) modified Response Evaluation Criteria in Solid Tumors tumor response I.I (modified RECIST 1.1) small cell lung cancer (sclc
下载PDF
Progress in the diagnosis and treatment of extensive-stage small cell lung cancer 被引量:3
4
作者 Fei Xu Xiaoli Ren +4 位作者 Yuan Chen Qianxia Li Ruichao Li Yu Chen Shu Xia 《Oncology and Translational Medicine》 2019年第1期33-42,共10页
Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant tumors globally each year. Small cell lung cancer(SCLC) accounts for approximately 15% of newly diagnosed lung cancers ... Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant tumors globally each year. Small cell lung cancer(SCLC) accounts for approximately 15% of newly diagnosed lung cancers each year, but its annual death toll accounts for 25% of that of lung cancer. We summarized relevant clinical studies to elaborate the epidemiology, pathological and clinical characteristics and the treatment status of small cell lung cancer. This paper first described the epidemiology and the pathological and clinical characteristics of SCLC and the systematic treatment of extensive-stage SCLC and then introduced the current targeted therapy and immunotherapy for SCLC to provide clinicians and patients with a more systematic, comprehensive, and beneficial treatment regimen. We expect that these studies can provide clinicians with a clear direction in molecularly targeted therapy or immunotherapy, so that a treatment approach with better antitumor effects and longer-lasting clinical benefits can be provided to the patients. 展开更多
关键词 small cell lung cancer (sclc) extensive-stage TARGETED therapy IMMUNOThERAPY
下载PDF
Whole brain radiotherapy concomitant or sequential Vm26/DDP in treating small cell lung cancer patients with brain metastases 被引量:1
5
作者 Mingyue Liu Yun Zhou +3 位作者 Qian Han Tianhui Gao Zhifen Luo Wenyu Wang 《The Chinese-German Journal of Clinical Oncology》 CAS 2010年第1期17-21,共5页
Objective: The aim of the study was to compare efficacies and safeties of 2 different treatments of whole brain radiotherapy (WBRT) sequential or concomitant Vm26/DDP for small cell lung cancer (SCLC) patients wi... Objective: The aim of the study was to compare efficacies and safeties of 2 different treatments of whole brain radiotherapy (WBRT) sequential or concomitant Vm26/DDP for small cell lung cancer (SCLC) patients with brain metastases. Methods: A total of 39 patients were randomly divided into sequential chemoradiotherapy regime (A group, 20 patients) and concomitant chemoradiotherapy regime (B group, 19 patients). The close of WBRT was 36 Gy in 18-20 fractions, chemotherapy of Vm26/DDP regimen with teniposide 60 mg/m^2 on dl to d3 and cisplatin 20 mg/m^2 on dl to d5, repeating every 3 weeks. The response was evaluated after WBRT and 2 cycles of chemotherapy. Results: Total response rates of A and B groups were 70.0% and 78.9% respectively (P = 0.520). The median survival was 11 months in A group and 10 months in B group. Six, twelve and eighteen months cumulative survival rates of A and B groups were 75.0%, 42.5%, 26.2%, and 81.6%, 26.4%, 10.5%, respectively (χ^2 = 0.383, P 〉 0.05). Response rate and the number of brain metastases were independent prognostic factors. Conclusion: Both sequential and concomitant chemoradiotherapy groups are effective, and the main toxicity with myelosuppression is tolerable after therapy. It can be applied firstly and effectively to the SCLC patients with brain metastases in clinic. 展开更多
关键词 small cell lung cancer (sclc brain metastases ChEMORADIOThERAPY VM26 DDP survival analysis
下载PDF
Comparative study of induction chemotherapy and chemoradiotherapy in the treatment of limited-disease small cell lung cancer with ipsilateral pleural effusion 被引量:1
6
作者 Ying Liu Xuerong Zuo +1 位作者 Caixia Zhang Ying Cheng 《The Chinese-German Journal of Clinical Oncology》 CAS 2012年第3期149-152,共4页
Objective:The aim of the study was to explore the effects and side effects of induction chemotherapy followed by chemoradiotherapy for limited-disease small cell lung cancer (LD-SCLC) patients with ipsilateral pleural... Objective:The aim of the study was to explore the effects and side effects of induction chemotherapy followed by chemoradiotherapy for limited-disease small cell lung cancer (LD-SCLC) patients with ipsilateral pleural effusion.Methods:From January 2005 to May 2009,52 LD-SCLC patients with ipsilateral pleural effusion were treated with induction chemotherapy first.The regimen was taken as follows:etoposide 100 mg iv,d1-d5,cisplatin 25 mg/m2 iv,d1-d3 or CBP AUC 4 iv,d1.Three-week therapy was a cycle.According to pleural effusion status after 2-4 cycles induction chemotherapy,patients got disappearance of pleural effusion after chemotherapy were underwent thoracic radiotherapy (TRT;50 Gy/25 fraction) or same chemotherapy regimen;patients without disappearance or with increasing of pleural effusion after chemotherapy were given same chemotherapy regimen.Therapeutic effect was evaluated every two cycles according to RECIST 1.0 and side-effects were evaluated every cycle according to NCI-CTC AE Grades.All patients were followed up,and the median follow-up time was 26 months.Results:The response rate of patients was 80.7% (42/52) after induction chemotherapy and 34 patients got disappearance of pleural effusion.The median survival time,1-and 2-year survival rates were 15.4 months,76.9% (40 /52) and 38.5% (20 /52) respectively.The median survival time,1-and 2-year survival rates of patients with pleural effusion remission received chest radiotherapy (A group,n=20),patients with pleural effusion remission received chemotherapy (B group,n=14) and patients without pleural effusion remission received chemotherapy (C group,n=18) were 21.5 months,14.4 months,12.5 months,80.0%,64.3%,55.6% and 35%,21.4%,11.1%,respectively.Main side effects were grades 1-2,including myelosuppression,fatigue,nausea and vomiting.No therapeutic related death was occurred.Conclusion:Induction chemotherapy plus chemoradiotherapy has shown better effect in prolonging survival of small cell lung cancer (SCLC) patients with ipsilateral pleural effusion than chemotherapy alone.The patients with decreased ipsilateral pleural effusion may receive benefit from subsequent TRT. 展开更多
关键词 small cell lung cancer (sclc ChEMOThERAPY ChEMORADIATION
下载PDF
Progress in diagnosis and treatment of small cell lung cancer with integrated traditional Chinese and Western medicine 被引量:1
7
作者 Yao Li Qing-Lu Wu +1 位作者 Ke-Xin Yu Fan Yang 《TMR Integrative Medicine》 2022年第8期1-7,共7页
Lung cancer is one of the most common major diseases that seriously threaten human health,lung cancer includes small cell lung cancer(SCLC)and non-small cell lung cancer(NSCLC).Although patients with SCLC account for ... Lung cancer is one of the most common major diseases that seriously threaten human health,lung cancer includes small cell lung cancer(SCLC)and non-small cell lung cancer(NSCLC).Although patients with SCLC account for about 20%of the total number of patients with lung cancer,the mortality rate is much higher than that of patients with NSCLC.Integrated traditional Chinese and Western medicine has obvious advantages in the treatment of patients with SCLC.According to the relevant literature reports on the treatment of SCLC in recent years,this article will summarize the research progress of integrated traditional Chinese and western medicine in the treatmentof SCLC from the aspects of traditional Chinese medicine(TCM)combined with surgery,chemotherapy,radiotherapy,and molecular targeted therapy. 展开更多
关键词 small cell lung cancer(sclc) integrated traditional Chinese and Western medicine progress in diagnosis and treatment
下载PDF
Treatment of etoposide capsule combined with cisplatin or carboplatin in elderly patients with small cell lung cancer
8
作者 Guanzhong Zhang Zhaozhe Liu +5 位作者 Tao Han Fang Guo Qingqing Sun Yanan Ge Yaling Han Xiaodong Xie 《The Chinese-German Journal of Clinical Oncology》 CAS 2014年第11期528-531,共4页
We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to Novembe... We aimed to explore the efficacy and safety of etoposide capsule combined with cisplatin or carboplatin in the treatment of elderly patients with small cell lung cancer (SCLC). Methods: From October 2011 to November 2013, 32 elderly patients (71-79 years old) with histopathologically confirmed SCLC in General Hospital of Shenyang Military Region (China) were enrolled in the research. The patients were administrated with lastet capsule 150-175 mg, dl-5, combined with cisplatin 20 mg/m^2 dl-3 or carbopiatin AUC = 5, applied over 2 days. Twenty-one days were 1 treatment cycle. Results:After treatments, 2 cases acquired complete response (CR), 19 cases acquired partial response (PR), 8 cases acquired stable disease (SD), and 3 cases had progression of disease (PD). The objective response rate was 65.6% (21/32), disease control rate was 90.6% (29/32). The median time of progression-free survival (PFS) was 6.9 months, the median survival time was 14.0 months, and 1 year survival rate was 62.4%. The main adverse reactions of 1/11 leukopenia and gastrointestinal reaction were observed. Conclusion: Etoposide capsule combined with cisplatin or carboplatin therapy have curative effect and good tolerance in elderly patients with SCLC. 展开更多
关键词 small cell lung cancer (sclc etoposide capsule CISPLATIN CARBOPLATIN ELDERLY
下载PDF
The clinical observation of combined chemotherapy of irinotecan and cisplatin in the treatment of relapsed advanced small cell lung cancer
9
作者 Zhonghai Ren Chenghui Zhang Ming Li 《The Chinese-German Journal of Clinical Oncology》 CAS 2008年第9期506-508,共3页
Objective: To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cell lung cancer (SCLC). Methods: Eligible patients with SCLC who had progressed or relapsed af... Objective: To evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced small cell lung cancer (SCLC). Methods: Eligible patients with SCLC who had progressed or relapsed after therapy were treated with cisplatin and irinotecan. The regimen consisted of irinotecan 60 mg/m^2 on days 1, 8, 15 and cisplatin 60 mg/m^2 on day 1; the plan was given every 28 days. Results: In 23 evaluable patients, responses included 5 complete remissions and 7 partial remissions (overall response rate, 43.4%), 6 patients had stable disease and 7 had progressive disease. Median time to progression and median survival were 4.6 and 8.3 months. The main toxicities were the hematologic toxicity, nausea and vomiting. Grade Ⅲ, IV leukopenia were seen in 15 patients (65.2%), thrombocytopenia was seen in 8 patients (34.8%); Nausea and vomiting were seen in 19 patients (82.6%); Grade Ⅲ, IV nausea and vomiting were seen in 4 patients (65.2%) and diarrhea was seen in 20 patients (87.0%). There were no treatment-related deaths. Conclusion: The combination of irinotecan and cisplatin is highly active and tolerable in patients with relapsed SCLC when it is administered as second-line treatment. 展开更多
关键词 IRINOTECAN CISPLATIN small cell lung cancer (sclc ChEMOThERAPY
下载PDF
Ubiquitin-specific protease 1 facilitates tumor immune escape from natural killer cells and predicts the prognosis in small cell lung cancer
10
作者 SHIQIN JIANG YICHUN TANG +2 位作者 FENG MA YUCHUN NIU LEI SUN 《Oncology Research》 SCIE 2025年第1期213-224,共12页
Objective:Small cell lung cancer(SCLC)is commonly recognized as the most fatal lung cancer type.Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers,their benefits are limite... Objective:Small cell lung cancer(SCLC)is commonly recognized as the most fatal lung cancer type.Despite substantial advances in immune checkpoint blockade therapies for treating solid cancers,their benefits are limited to a minority of patients with SCLC.In the present study,novel indicators for predicting the outcomes and molecular targets for SCLC treatment were elucidated.Methods:We conducted bioinformatics analysis to identify the key genes associated with tumor-infiltrating lymphocytes in SCLC.The functional role of the key gene identified in SCLC was determined both in vitro and in vivo.Results:A significant correlation was observed between patient survival and CD56dim natural killer(NK)cell proportion.Furthermore,we noted that the hub gene ubiquitin-specific protease 1(USP1)is closely correlated with both CD56dim NK cells and overall survival in SCLC.Bioinformatics analysis revealed that USP1 is upregulated in SCLC.In addition,gene set enrichment analysis revealed that USP1 overexpression hinders NK cell-mediated immune responses.By co-cultivating NK-92 cells with SCLC cells,we demonstrated that NK cell cytotoxicity against SCLC could be improved either via USP1 knock-down or pharmacological inhibition.Furthermore,using a nude-mice xenograft tumor model,we noted that USP1 inhibition effectively suppressed tumor proliferation and increased the expression of NK cell-associated markers.Conclusions:Our study findings highlight the importance of NK cells in regulating SCLC.USP1 overexpression can inhibit NK cell-mediated immunity;therefore,USP1 may serve not only as a prognostic biomarker but also as a potential molecular target of SCLC therapy. 展开更多
关键词 Ubiquitin-specific protease 1(USP1) Natural killer(NK)cell small cell lung cancer(sclc) Prognosis Immune escape
下载PDF
下调ODC1对人SCLC细胞H82、H69增殖、凋亡及铂类药物敏感性的影响
11
作者 高翔鹏 王晓芳 +3 位作者 贺文艺 李玉苗 宋瑾 贾友超 《河北大学学报(自然科学版)》 CAS 北大核心 2024年第2期173-181,共9页
为探索下调鸟氨酸脱羧酶1(ornithine decarboxylase1, ODC1)对人小细胞肺癌(small cell lung cancer, SCLC)细胞H82、H69增殖、凋亡及铂类药物敏感性的影响,检测了人SCLC细胞系ODC1的表达水平,并利用LV-NC/ODC1-RNAi慢病毒感染H82、H69... 为探索下调鸟氨酸脱羧酶1(ornithine decarboxylase1, ODC1)对人小细胞肺癌(small cell lung cancer, SCLC)细胞H82、H69增殖、凋亡及铂类药物敏感性的影响,检测了人SCLC细胞系ODC1的表达水平,并利用LV-NC/ODC1-RNAi慢病毒感染H82、H69细胞后,通过实时荧光定量PCR(qPCR)和免疫印迹实验(West1ern blot)检测ODC1在mRNA和蛋白水平的表达.CCK-8法、软琼脂克隆形成实验、流式细胞术、Western blot等检测下调ODC1后细胞增殖、凋亡及对铂类药物敏感性的变化.结果显示,ODC1在人SCLC细胞系中多数高表达,且下调ODC1后人SCLC细胞H82、H69增殖减慢,凋亡明显增加,药物敏感性增强.说明下调ODC1抑制H82、H69细胞增殖,促进细胞凋亡,增强细胞对铂类药物的敏感性. 展开更多
关键词 鸟氨酸脱羧酶1(ODC1) 小细胞肺癌(sclc) 增殖 凋亡 药物敏感性
下载PDF
替莫唑胺对小细胞肺癌H446细胞的凋亡诱导作用 被引量:4
12
作者 苏雷 史鸿云 +4 位作者 刘妙玲 商琰红 贾友超 刘斌 胡玲 《中国生化药物杂志》 CAS 2015年第4期55-58,共4页
目的探讨替莫唑胺对小细胞肺癌(SCLC)细胞H446的凋亡诱导作用及具体分子生物学机制。方法通过MTT法检测替莫唑胺对H446细胞活力的影响;流式细胞术检测替莫唑胺对H446细胞周期的影响;Western blot分析磷脂酰肌醇-3-激酶(PI3K)/AKT通路的... 目的探讨替莫唑胺对小细胞肺癌(SCLC)细胞H446的凋亡诱导作用及具体分子生物学机制。方法通过MTT法检测替莫唑胺对H446细胞活力的影响;流式细胞术检测替莫唑胺对H446细胞周期的影响;Western blot分析磷脂酰肌醇-3-激酶(PI3K)/AKT通路的激活状况及其下游靶基因细胞周期蛋白B1(Cyclin B1),细胞分裂周期基因2(Cdc2),Bax,Bcl-2和生存素(Survivin)的表达。结果替莫唑胺(50,100,200μmol/L)可显著抑制细胞的活力,并且在48h抑制程度最高,并使细胞周期阻滞在G2/M期。Western blot结果显示替莫唑胺能抑制PI3K表达及Akt磷酸化,进而下调Cyclin B1,Cdc2,Bcl-2和Survivin的表达,上调Bax的表达。结论替莫唑胺可通过阻断PI3K/AKT信号通路来诱导SCLC细胞H446凋亡。 展开更多
关键词 替莫唑胺 小细胞肺癌细胞h446 凋亡 PI3K/AKT信号通路
下载PDF
缺氧对人小细胞肺癌H446细胞DNA错配修复基因MLH1、MSH2表达的影响及其机制探讨 被引量:4
13
作者 郭芮伶 吴国明 戢福云 《中国癌症杂志》 CAS CSCD 2008年第1期26-29,共4页
背景与目的:缺氧对DNA错配修复系统(mismatch repair,MMR)活性的调控是肿瘤细胞遗传不稳定的重要原因,但其机制尚不完全清楚。本研究拟观察缺氧状态下人小细胞肺癌H446细胞DNA错配修复基因MLH1、MSH2的表达变化,初步探讨DNA甲基化在其... 背景与目的:缺氧对DNA错配修复系统(mismatch repair,MMR)活性的调控是肿瘤细胞遗传不稳定的重要原因,但其机制尚不完全清楚。本研究拟观察缺氧状态下人小细胞肺癌H446细胞DNA错配修复基因MLH1、MSH2的表达变化,初步探讨DNA甲基化在其中的作用。方法:应用RT-PCR、Western blot等方法检测H446细胞在缺氧状态下以及甲基转移酶抑制剂5-氮杂-2′-脱氧胞苷(5-Aza-CdR)处理后MLH1、MSH2基因的表达水平,同时,采用甲基化特异性PCR(MSP)方法检测MLH1、MSH2基因启动子CpG岛甲基化状态。结果:缺氧状态下,H446细胞MLH1、MSH2基因在转录和翻译水平均显著性降低。同时,随着缺氧时间延长,MLH1基因启动子逐渐由非甲基化状态、部分甲基化状态转变为完全甲基化状态,而MSH2基因启动子则直接由非甲基化状态转变为完全甲基化状态。甲基转移酶抑制剂5-Aza-CdR可使MLH1、MSH2基因表达水平有所恢复,但去除5-Aza-CdR后其表达再次下调。结论:启动子甲基化可能是缺氧诱导H446细胞显著性下调MLH1、MSH2基因表达的重要机制,甲基转移酶抑制剂5-Aza-CdR可恢复其表达。 展开更多
关键词 缺氧 小细胞肺癌 DNA错配修复 启动子甲基化 5-Aza—CdR
下载PDF
小细胞肺癌组织显著低表达的SPIDR通过降低血清依赖促进NCI-H446细胞增殖 被引量:1
14
作者 张泽忠 贾玉琳 +7 位作者 其力格尔 方一 李春晖 厉建蕾 顾晔 邓子新 张海平 马伟 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2018年第10期1026-1033,共8页
目的:探讨同源重组修复途径关键调控蛋白SPIDR在小细胞肺癌(small cell lung cancer,SCLC)中的作用与机制。方法:收集2013年1月至2015年1月上海肺科医院进行肿瘤手术切除、气管镜穿刺的SCLC患者癌组织标本60例及正常人群肺组织标本44例,... 目的:探讨同源重组修复途径关键调控蛋白SPIDR在小细胞肺癌(small cell lung cancer,SCLC)中的作用与机制。方法:收集2013年1月至2015年1月上海肺科医院进行肿瘤手术切除、气管镜穿刺的SCLC患者癌组织标本60例及正常人群肺组织标本44例,qRT-PCR检测临床组织样本SPIDR mRNA表达水平;经稳定过表达SPIDR改变NCI-H446细胞表达水平后,采用MTT、小鼠荷瘤实验等实验方法,在体内、体外探究SPIDR表达水平对SCLC细胞增殖等影响。结果:吸烟与患者SCLC的发生显著有关(P<0.01);SPIDR m RNA在SCLC组织样本中的表达显著低于正常肺组织(P<0.01)。人肺胚成纤维细胞株MRC-5中SPIDR mRNA和蛋白表达水平明显高于SCLC细胞株NCI-H446(均P<0.05)。在10%胎牛血清常规培养体系中,过表达SPIDR对NCI-H446细胞增值和化疗药物敏感性无明显影响(均P>0.05),但小鼠荷瘤实验从第9天开始,过表达SPIDR组(pMSCV-SPIDR)的瘤体积与原始NCI-H446组和空载体组(pMSCV)开始出现明显差异,第27天pMSCV-SPIDR组移植瘤平均体积分别比原始NCI-H446组与空载体组缩小58.99%和61.84%(均P<0.01)。在含1%~3%胎牛血清的非常规培养体系中,过表达SPIDR的NCI-H446细胞增殖速度显著低于原始NCI-H446组和空载体组(P<0.05或P<0.01)。结论:SCLC组织中SPIDR表达水平明显低于正常肺组织,过表达SPIDR的NCI-H446细胞体内及体外低血清含量培养(<3%)生长速度显著低于对照组,表明SPIDR以低血清浓度依赖方式影响SCLC细胞增殖。 展开更多
关键词 小细胞肺癌 NCI-h446细胞 同源重组修复 SPIDR 血清依赖
下载PDF
Gender-Related Survival in Different Stages of Lung Cancer—A Population Study over 20 Years 被引量:1
15
作者 Gunnar Svensson Sven-Borje Ewers +1 位作者 Ola Ohlsson Hakan Olsson 《Open Journal of Internal Medicine》 2014年第3期47-58,共12页
Introduction: Tumour stage is the most important prognostic factor in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The aim of this study was to evaluate if female gender was a prognostic facto... Introduction: Tumour stage is the most important prognostic factor in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The aim of this study was to evaluate if female gender was a prognostic factor in different tumour stages in relation to histology and given therapy. Methods: From 1989-2008, 1497 patients in eastern Scania, in southern Sweden with 202,000 inhabitants, were referred and prospectively registered. Tumour stage, performance status, lung cancer type and primary therapy were registered. Results: In NSCLC, female patients in stages 1 and 2 who were treated with surgery had a better 5-year survival rate (79.4%), compared to males (60.6%;p = 0.0004). Female patients in stage 3 with active therapy (surgery and/or radiotherapy and/or chemotherapy) had a better 5-year survival than males (20.6% vs. 10.5%, respectively, p = 0.0006). Female patients with adenocarcinoma were favourable in stages 1-3. In stage 4, there was no survival difference between females and males. In SCLC, females with limited disease (LD) and active therapy (chemotherapy ±?radiotherapy ± surgery) had a higher 5-year survival rate (28%) than males (5.6%);p = 0.001. Females with extensive disease (ED) and active therapy (chemotherapy ± radiotherapy) had a better 5-year survival (3.9%) compared to males (0.7%);p = 0.023. In multivariate analyses, patient performance status at diagnosis was also an independent prognostic factor in all tumour stages of lung cancer. Conclusions: This population-based study corroborates a female survival advantage in NSCLC stages 1-3, but not in metastatic stage 4, and this is also demonstrated for the adenocarcinoma subgroup. The study also confirms better prognosis in females with SCLC in both LD and ED. The study also demonstrates the importance of patient performance status as a prognostic factor in all stages of lung cancer. 展开更多
关键词 GENDER Performance Status Prognostic Factor Nsclc(Non-small cell lung cancer) sclc(small cell lung cancer) Tumour Stage
下载PDF
MULTIMODALITY THERAPY INCLUDING SURGICAL RESEC-TION FOR LIMITED SMALL CELL LUNG CANCER
16
作者 陈肖嘉 李世业 +4 位作者 左东岭 刘树库 白连启 阎东杰 黄志英 《Chinese Medical Journal》 SCIE CAS CSCD 1995年第9期51-53,共3页
From 1975 through 1990, 199 patients with limited small cell lung cancer (LSCLC) were subjected to multimodality treatment including surgical resection combined with chemotherapy or chemoradiotherapy in our department... From 1975 through 1990, 199 patients with limited small cell lung cancer (LSCLC) were subjected to multimodality treatment including surgical resection combined with chemotherapy or chemoradiotherapy in our department. The median postoperative survival time of the 199 patients was 39 months, and the 5-year survival rate was 26%, which was decreased with increase of tumor-stage. In comparison of the survival time of patients in Stage Ⅰ and those in Stage Ⅲa, there was a significant difference (P<0.01). There were no significant differences in survival rate of 3 and 5 years between the patients receiving chemotherapy prior to or after surgical resection. The improvement in survival was documented by surgical resection combined with chemotherapy or chemoradiotherapy for LSCLC. The effect of multimodality treatment is correlated with tumor P-TNM staging, the involvement of lymph node, especially that of the mediastinal lymph node, is a negative factor influencing the prognosis. Surgical resection as an initial management, followed by chemotherapy or chemoradiotherapy may be indicated in LSCLC patients of Stage Ⅰ, Stage Ⅱ and some Stage Ⅲa as the cancer can be resected completely. 展开更多
关键词 sclc In MULTIMODALITY ThERAPY INCLUDING SURGICAL RESEC-TION FOR LIMITED small cell lung cancer TNM
原文传递
Serpin家族H成员1在非小细胞肺癌中的表达及其作用机制研究
17
作者 刘业锋 李飞 谢伟 《中国社区医师》 2024年第22期11-13,169,共4页
目的:分析Serpin家族H成员1(SERPINH1)在非小细胞肺癌(NSCLC)中的表达及其作用机制。方法:选取2022年1月-2023年12月于句容市人民医院进行肿瘤切除手术的60例NSCLC患者的肿瘤组织和癌旁组织进行研究。从癌症基因组图谱(TCGA)数据集获得N... 目的:分析Serpin家族H成员1(SERPINH1)在非小细胞肺癌(NSCLC)中的表达及其作用机制。方法:选取2022年1月-2023年12月于句容市人民医院进行肿瘤切除手术的60例NSCLC患者的肿瘤组织和癌旁组织进行研究。从癌症基因组图谱(TCGA)数据集获得NSCLC组织和正常组织的RNA测序(RNAseq)数据和相应的临床信息,免疫组化评估NSCLC组织中SERPINH1表达,并进行体外细胞实验分析SERPINH1对人肺腺癌细胞系A549细胞增殖、迁移和侵袭的影响。结果:与正常组织相比,SERPINH1 mRNA在NSCLC组织中表达显著上调。SERPINH1高表达患者总生存期和疾病特异性生存期短于SERPINH1低表达患者。NSCLC组织SERPINH1蛋白表达水平高于癌旁组织(P<0.001)。SERPINH1过表达组A549细胞增殖、迁移和侵袭能力高于空白组(P<0.001),SERPINH1敲低组A549细胞体外增殖、迁移和侵袭能力低于空白组(P<0.001)。结论:SERPINH1在NSCLC中高表达,与肿瘤增殖、转移密切相关,可作为治疗NSCLC的潜在靶点。 展开更多
关键词 非小细胞肺癌 Serpin家族h成员1 增殖 迁移 侵袭
下载PDF
扶正抗癌方联合吉非替尼对肺癌H1650细胞株裸鼠移植瘤的抑制作用 被引量:11
18
作者 杨小兵 吴万垠 +2 位作者 龙顺钦 邓宏 韩守威 《广东医学》 CAS 北大核心 2015年第23期3581-3585,共5页
目的研究扶正抗癌方联合吉非替尼对人非小细胞肺癌细胞株H1650裸鼠移植瘤的抑制作用及其对细胞增殖的影响。方法在裸鼠上接种对吉非替尼耐药的细胞株(H1650细胞株),造模成功后随机分对照组、吉非替尼组、中药低剂量组、中药高剂量组、... 目的研究扶正抗癌方联合吉非替尼对人非小细胞肺癌细胞株H1650裸鼠移植瘤的抑制作用及其对细胞增殖的影响。方法在裸鼠上接种对吉非替尼耐药的细胞株(H1650细胞株),造模成功后随机分对照组、吉非替尼组、中药低剂量组、中药高剂量组、吉非替尼联合中药低剂量组、吉非替尼联合中药高剂量组,每组10只。各组处理依次为:生理盐水0.2 m L、吉非替尼50 mg/(kg·d)、扶正抗癌方62 mg/(kg·d)、扶正抗癌方124 mg/(kg·d)、吉非替尼50 mg/(kg·d)+扶正抗癌方62 mg/(kg·d)、吉非替尼50 mg/(kg·d)+扶正抗癌方124 mg/(kg·d)。胃内给药15 d后观察不同组别的裸鼠肿瘤生长情况、抑瘤率,用Ki-67免疫组化分析对细胞增殖的影响。结果与对照组比较,吉非替尼联合中药低剂量组及中药高剂量组的瘤体体积差异有统计学意义(P<0.01)。与对照组比较,吉非替尼联合中药高剂量组的瘤重明显下降,差异有统计学意义(P<0.01)。细胞增殖率依次为对照组(63.94±8.19)%、吉非替尼组(57.11±7.58)%、中药低剂量组(54.39±8.85)%、中药高剂量组(55.94±12.26)%、吉非替尼联合中药低剂量组(50.61±8.81)%及吉非替尼联合中药高剂量组(48.72±11.63)%,细胞增殖呈下降趋势,与对照组比较,各用药组差异有统计学意义。与吉非替尼组比较,吉非替尼联合中药低剂量组、吉非替尼联合中药高剂量组的细胞增殖率差异有统计学意义(P<0.05);与中药高剂量组比较,吉非替尼联合中药高剂量组细胞增殖率差异有统计学意义(P=0.029)。结论吉非替尼联合扶正抗癌方对裸鼠非小细胞肺癌H1650移植瘤的抑制优于吉非替尼或扶正抗癌方;联合用药对H1650移植瘤细胞增殖的抑制优于吉非替尼或扶正抗癌方单药治疗,两者有协同作用,吉非替尼联合中药高剂量组效果最佳。 展开更多
关键词 非小细胞肺癌 扶正抗癌方 吉非替尼 h1650 协同作用
下载PDF
循环肿瘤细胞联合血清胃泌素释放前肽及神经元特异性烯醇化酶水平对SCLC化疗疗效的评估意义 被引量:9
19
作者 苗欣 赵家义 +2 位作者 范银星 李佳浓 韩一平 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2017年第4期362-366,共5页
目的:探讨外周血循环肿瘤细胞(circulating tumor cell,CTC)数量联合胃泌素释放前肽(gastrin releasing peptide,pro-GRP)及神经元特异性烯醇化酶(neuron specific enolase,NSE)对小细胞肺癌(small cell lung cancer,SCLC)患者化疗疗效... 目的:探讨外周血循环肿瘤细胞(circulating tumor cell,CTC)数量联合胃泌素释放前肽(gastrin releasing peptide,pro-GRP)及神经元特异性烯醇化酶(neuron specific enolase,NSE)对小细胞肺癌(small cell lung cancer,SCLC)患者化疗疗效的评估意义。方法:收集2015年10月1日至2016年12月30日长海医院呼吸与危重症科收治的40例SCLC患者作为观察对象,分别于第1、3周期化疗前抽取患者外周血,检测其CTC、pro-GRP及NSE水平,分析CTC数目及其联合pro-GRP、NSE水平与化疗疗效的关系;第1、3周期化疗前行胸部CT,对比CTC、pro-GRP及NSE联合判断化疗疗效与实体瘤疗效评价标准(response evaluation criteria in solid tumors,RECIST)标准判断化疗疗效的差异性;分析CTC数与患者临床特征的关系。结果:40例SCLC患者中初次、二次检测到CTC的阳性率为82.5%、87.5%。化疗后外周血CTC数下降越多,疗效越好。根据RECIST标准,肿瘤进展组与肿瘤控制组CTC的变化差异有统计学意义(P<0.05)。CTC数目评价标准下,肿瘤控制与否与患者的年龄、性别、吸烟与否、初诊时肿瘤大小、肿瘤分期无明显关联(P>0.05)。CTC数目评价化疗疗效与RECIST两者存在一致性。联合检测CTC、pro-GRP及NSE,三者量值评价化疗疗效与RECIST疗效评价结果同样一致(P>0.05),且三者联合检测可提高疗效判断的灵敏性。结论:CTC数目与化疗疗效呈负相关,联合检测CTC、pro-GRP及NSE评估SCLC患者化疗疗效灵敏性更高。 展开更多
关键词 小细胞肺癌 循环肿瘤细胞 胃泌素释放前肽 神经元特异性烯醇化酶 化疗疗效
下载PDF
伊立替康联合洛铂治疗复发性广泛期小细胞肺癌(SCLC)的临床研究 被引量:5
20
作者 伍志新 陈立军 +1 位作者 宋文军 黄彬彬 《现代肿瘤医学》 CAS 2014年第6期1344-1346,共3页
目的:观察伊立替康联合洛铂方案治疗复发性小细胞肺癌(SCLC)的疗效和毒副反应。方法:选取36例SCLC患者,予伊立替康200mg/m2加入生理盐水250ml中,稀释后静滴1.5h,第1天;洛泊35mg/m2加入5%葡萄糖500ml中,稀释后静滴2h,第1天,每21d为1个周... 目的:观察伊立替康联合洛铂方案治疗复发性小细胞肺癌(SCLC)的疗效和毒副反应。方法:选取36例SCLC患者,予伊立替康200mg/m2加入生理盐水250ml中,稀释后静滴1.5h,第1天;洛泊35mg/m2加入5%葡萄糖500ml中,稀释后静滴2h,第1天,每21d为1个周期,2个周期后评价疗效和毒副反应。结果:36例均可评价疗效,完全缓解(CR)1例,部分缓解(PR)13例,疾病稳定(SD)11例,疾病进展(PD)11例,客观缓解率(ORR)为38.9%,疾病控制率(DCR)为69.4%,中位无进展生存期(PFS)为4.6个月,中位生存期(OS)为7.8个月。毒副反应主要为血液学毒性和消化道毒性,3/4级白细胞减少、血红蛋白减少和血小板减少发生率分别为41.7%(15/36)、50.0%(18/36)、72.2%(26/36);腹泻发生率为69.4%(25/36),其中3、4级腹泻为13.9%(5/36)。全组无毒性相关死亡。结论:伊立替康联合洛铂方案用于治疗复发性SCLC有较好的疗效,毒副反应可耐受。 展开更多
关键词 伊立替康 洛铂 小细胞肺癌 化疗 复发
下载PDF
上一页 1 2 7 下一页 到第
使用帮助 返回顶部